Greer Capital Advisors - Investor Profile and Portfolio

Developer of vaccines for infectious diseases including influenza, hepatitis B, and solid tumors. The company has NasoVAX, an intranasally administered recombinant influenza vaccine, HepTcell, an immunotherapy for the chronic hepatitis B virus infection, ALT-801 for non-alcoholic steatohepatitis, T-COVID intranasal therapeutic for covid, and nasoshield for anthrax.

Morphotek develops biological-based products to treat cancer, inflammation, and infectious diseases. Has several monoclonal antibodies (mAbs) in clinical development for cancer and inflammatory disease. Its lead program, farletuzumab is for patients with platinum-sensitive, relapsed ovarian cancer (received orphan drug designation) and 1st line non-small cell lung cancer. Its other lead antibody monoclonal programs, amatuximab, and ontuxizumab. Amatuximab, ontuxizumab has received orphan drug designation for malignant pleural mesothelioma and for sarcoma respectively. Its other investigational mAbs programs are against inflammatory and infectious diseases.

Diagnostics and digital pathology solutions for oncology. It provide assistance and insight into what therapies will work best for these patients, and continue with follow-up and case monitoring. The tests they offer include Breast, Colorectal, Leukemia, Lung, Melanoma Cancer testing. The diagnostic technologies used include Chromosome Analysis, Flow Cytometry, Polymerase Chain Reaction, Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry, In-Situ Hybridization, Nucleic Acid Microarrays, Multiplexed Immunofluorescence.

Cumberland Pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. Its markets Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the US; and Kristalose® (lactulose) for Oral Solution, a prescription laxative, Vaprisol® (conivaptan) Injection, for the treatment of hyponatremia and Omeclamox®-Pak for the treatment of H. pylori and duodenal ulcer disease. In early 2011, we acquired the rights to Hepatoren® (ifetroban) injection, and have initiated clinical development to treat patients suffering from hepatorenal syndrome (Phase 2/3), a life-threatening condition involving progressive kidney failure for which there is no FDA-approved pharmaceutical treatment.